Windlas Biotech (WINDLAS) Stock Overview
A contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
WINDLAS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Windlas Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹854.05 |
| 52 Week High | ₹1,140.00 |
| 52 Week Low | ₹665.10 |
| Beta | 0.26 |
| 1 Month Change | 8.89% |
| 3 Month Change | -1.82% |
| 1 Year Change | -14.54% |
| 3 Year Change | 240.60% |
| 5 Year Change | n/a |
| Change since IPO | 109.76% |
Recent News & Updates
Windlas Biotech Limited's (NSE:WINDLAS) Popularity With Investors Is Under Threat From Overpricing
Jan 17
Solid Earnings May Not Tell The Whole Story For Windlas Biotech (NSE:WINDLAS)
Nov 14Here's Why We Think Windlas Biotech (NSE:WINDLAS) Might Deserve Your Attention Today
Nov 11Recent updates
Windlas Biotech Limited's (NSE:WINDLAS) Popularity With Investors Is Under Threat From Overpricing
Jan 17Solid Earnings May Not Tell The Whole Story For Windlas Biotech (NSE:WINDLAS)
Nov 14Here's Why We Think Windlas Biotech (NSE:WINDLAS) Might Deserve Your Attention Today
Nov 11It Looks Like The CEO Of Windlas Biotech Limited (NSE:WINDLAS) May Be Underpaid Compared To Peers
Jul 22Should You Be Adding Windlas Biotech (NSE:WINDLAS) To Your Watchlist Today?
Mar 25What You Can Learn From Windlas Biotech Limited's (NSE:WINDLAS) P/E After Its 28% Share Price Crash
Feb 19Windlas Biotech (NSE:WINDLAS) Seems To Use Debt Quite Sensibly
Jan 28There May Be Underlying Issues With The Quality Of Windlas Biotech's (NSE:WINDLAS) Earnings
Nov 20Windlas Biotech Limited's (NSE:WINDLAS) 30% Share Price Surge Not Quite Adding Up
Nov 01Windlas Biotech (NSE:WINDLAS) Will Pay A Larger Dividend Than Last Year At ₹5.50
Sep 01Windlas Biotech Limited (NSE:WINDLAS) Stock Rockets 26% But Many Are Still Ignoring The Company
Aug 13Should You Be Adding Windlas Biotech (NSE:WINDLAS) To Your Watchlist Today?
Jul 30Even With A 27% Surge, Cautious Investors Are Not Rewarding Windlas Biotech Limited's (NSE:WINDLAS) Performance Completely
Jun 07Is Now The Time To Put Windlas Biotech (NSE:WINDLAS) On Your Watchlist?
Nov 03Windlas Biotech (NSE:WINDLAS) Is Increasing Its Dividend To ₹4.00
Aug 20Windlas Biotech (NSE:WINDLAS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
May 23Windlas Biotech Limited's (NSE:WINDLAS) Shares Lagging The Market But So Is The Business
Apr 07Shareholder Returns
| WINDLAS | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 0.6% | 0.6% | 1.6% |
| 1Y | -14.5% | -9.6% | 5.3% |
Return vs Industry: WINDLAS underperformed the Indian Life Sciences industry which returned -8.5% over the past year.
Return vs Market: WINDLAS underperformed the Indian Market which returned 4.9% over the past year.
Price Volatility
| WINDLAS volatility | |
|---|---|
| WINDLAS Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.8% |
| 10% least volatile stocks in IN Market | 3.5% |
Stable Share Price: WINDLAS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: WINDLAS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,346 | Komal Gupta | windlas.com |
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules.
Windlas Biotech Limited Fundamentals Summary
| WINDLAS fundamental statistics | |
|---|---|
| Market cap | ₹17.90b |
| Earnings (TTM) | ₹667.47m |
| Revenue (TTM) | ₹8.69b |
Is WINDLAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WINDLAS income statement (TTM) | |
|---|---|
| Revenue | ₹8.69b |
| Cost of Revenue | ₹5.38b |
| Gross Profit | ₹3.30b |
| Other Expenses | ₹2.64b |
| Earnings | ₹667.47m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 31.85 |
| Gross Margin | 38.03% |
| Net Profit Margin | 7.68% |
| Debt/Equity Ratio | 4.8% |
How did WINDLAS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/06 02:29 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Windlas Biotech Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.